References
- Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med.363, 1693–1703 (2010).
- Jørgensen JT. A challenging drug development process in the era of personalized medicine. Drug Discov. Today16(19–20), 891–897 (2011).
- Gerlinger M, Rowan AJ, Horswell S et al. Intratumour heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med.366, 883–892 (2012).
- Blair ED, Blakemore JA. Drug–diagnostic codevelopment: how to harness the value. Drug Discov. Today.16(19–20), 902–905 (2011).
- US FDA. Draft Guidance for Industry and Food and Drug Administration Staff – In Vitro Companion Diagnostic Devices. US FDA, USA (2011).
- Purvis DR, Thomas JA. IVDs: transforming the prospects for personalised medicine. Innovations in Pharmaceutical Technology40, 32–34 (2012).
- [No authors listed]. Where will new drugs come from? Lancet377(9760), 97 (2011).
- Herper M. The truly staggering cost of inventing new drugs. Forbes Magazine. 12 March 2012.
Website
- Episcom business intelligence report. Targeted cancer drugs, the launch landscape to 2018. 3 February 2012. www.espicom.com/ProdCat2.nsf/Product_Alt_URL_Lookup/targeted-cancer-drugs?OpenDocument